Antonio Llombart-Cussac
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
May 8, 2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
May 8, 2024Ann Oncol 2024
Goetz Matthew P, Toi Masakazu, Huober Jens, Sohn Joo Hyuk, Trédan Olivier, Park In Hae, Campone Mario, Chen S-C, Manso L M, Paluch-Shimon Shani, Freedman Orit C, O'Shaughnessy Joyce, Pivot X, Tolaney Sara M, Hurvitz Sara A, Llombart-Cussac Antonio, Andre Valerie A M, Saha A, van Hal G, Shahir Ashwin, Iwata H, Johnston Stephen R D
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Mouridsen H, Thürlimann B, Robidoux A, Llombart-Cussac A, Gligorov J, Doughty J, Blackwell K, Beckmann M, Lønning P, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.
Sep 30, 2010Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Sep 30, 2010Expert Rev Anticancer Ther 2010; 10:1825-1836
Mouridsen Henning T, Thürlimann Beat, Robidoux Andre, Llombart-Cussac Antonio, Gligorov Joseph, Doughty Julie, Blackwell Kimberly, Beckmann Matthias W, Lønning Per, Gnant Michael